行情

ACHN

ACHN

爱克莱恩
NASDAQ

实时行情|Nasdaq Last Sale

6.28
+0.02
+0.24%
已收盘, 17:42 11/19 EST
开盘
6.28
昨收
6.26
最高
6.35
最低
6.24
成交量
277.22万
成交额
--
52周最高
6.46
52周最低
1.290
市值
8.79亿
市盈率(TTM)
-11.6918
分时
5日
1月
3月
1年
5年

分析师评级

2位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

ACHN 新闻

  • EMA grants PRIME designation to Achillion's danicopan
  • seekingalpha.17小时前
  • Achillion Pharmaceuticals Option Alert: Mar 20 $7 Calls at the Ask: 5000 @ $0.051 vs 32023 OI; Ref=$6.295
  • Benzinga.19小时前
  • European Medicines Agency Grants PRIME Designation to Danicopan for Treatment of Paroxysmal Nocturnal Hemoglobinuria Patients Who Are Not Adequately Responding to a C5 Inhibitor
  • GlobeNewswire.22小时前
  • Alexion (ALXN) Up 10 % YTD on Soliris & Ultomiris Strength
  • Zacks.5天前

更多

所属板块

生物技术和医学研究
+2.16%
制药与医学研究
+0.78%

热门股票

名称
价格
涨跌幅

ACHN 简况

Achillion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system. The complement system is part of the human innate immune system. Its clinical compound from its complement inhibitor platform is ACH-4471. ACH-4471 is a potent and specific inhibitor of factor D, which demonstrated complete inhibition of the complement alternative pathway in human healthy volunteers in a Phase I clinical trial. The Company has discovered and advanced multiple compounds into clinical development, including sovaprevir, odalasvir, and ACH-3422 in its hepatitis C virus (HCV) program.
展开

Webull提供Achillion Pharmaceuticals, Inc.的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。